ASSESSMENT OF FIBRINOLYTIC ACTIVIT\' IN TYPE II DIABETIC PATIENTS WITH MICROALBUMINURIA

Abstract

Microalbuminuria is a marker of greatly increased cardiovascular morbidity and mortality for patients with NIDDM. The ' .

,I cause of this increase is multifactorial. Growing interest has

' focussed on the possible role of plasminogen activator inhibitor-!.

The aim of our present work was to assess the fibrinolytic activity in these patients and to correlate the findings to increased incidence of cardiovascular complications.

For this purpose, the present study was carried on 30 diabetic •' il ;/ patients who were randomly selected from the departments of

,/, Internal Medicine in Alexandria Main University Hospital. ,/.

Group 1: 15 patients with NIDDM -stage of microalbuminuria UAE=

30-300 mg/24 hrs.

Group II: 15 patients with NIDDM -stage of normalbuminuria UAE=

< 30 mg/24 hrs.

i i'